Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6

CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story.